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PENEMUAN AGONIS UNTUK PENGAKTIFAN PEROKSISOM 
PROLIFERATE GAMMA 
ABSTRAK 
Pengawalaturan Pembezaan Reseptor aktivasi Pembiakan Peroksisom Gamma (PPARγ) 
adalah superfamili reseptor nuklear faktor transkripsi yang diaktifkan oleh ligan. Dalam. 
Sistem biologi, PPARγmemainkan peranan yang penting dalam mengawal metabolism 
glukosa and lipid. Disebabkan oleh itu, PPARγ telah menarik perhatian yang besar 
sebagai sasaran yang berpotensi untuk mereka bentuk ubat yang baru untuk merayat 
penyakit diabetes jenis-2. PPARγ agonis, rosiglitazone, adalah ubat barisan pertama bagi 
miningkatkan sensitiviti insulin diabetes jenis-2. Walau bagaimanapun, kajian baru-baru 
ini menunjukan bahawa rosigkitazone menyebabkan kesam sampingan yang tidak 
diingini seperti pertambahan berat badan, edema dan pembendungan air. Oleh itu, 
adalah perlu untuk mengenalpasti agonis PPARγ yang kurang komplikasi.Dalam kajian 
ini, saringan virtual menggunakan pendekatan dok molekul telah dilakukan terhadap 
5000 sebatian, 3000 sebatian adalah dari pengkalan data Nature-Based Drug Discovery 
(NADI) dan 2000 sebatian telah diambil dari pengakalan data National Cancer Institute 
(NCI) Diversity set 1. 100 calon sebatian yang teratas mengikut tenaga pengikatan 
terendah seterusnya dianalisis berdasarkan nod pengikatan. Sebanyak empat sebatian 
telah dipilih dari pengkalan data NCI and dua tumbuhan (Temu kunci and Ketumbar) 
telah dipilih dari sumber asli Malaysia untuk menjalankan ujian in-vitro terhadap PPARγ. 
Dari hasil ujian, sebatian yang paling aktif dari pangkalan data NCI adalah NCI37245, 
PPARγ yang diaktifnya dengan kandungan EC50 43.6 nM. Manakala bagi tumbuhan –
tumbuhan yang terpilih, ekstrak mentah metanol Temu kunci adalah lebih aktif 
xviii 
 
berbanding dengan ketumbar. Ekstrak mentah Temu kunci mengaktifkan PPARγ pada 
kira-kira 1.5 kali gnda lebih tinggi berbanding dengan ketumbar (Prubahan kali ganda = 
1.6) dengan kandungan EC50, 0.13μg/mL. Oleh itu, secara kesimpulannya, pendokan 
berasaskan teknik saringan virtual telah berjaya dibangunkan dan boleh digunakan untuk 
memilih ligan PPARγ yang berpotensi daripada molekul-molekul kecil.  
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DISCOVERY OF PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTOR GAMMA AGONIST 
ABSTRACT  
Peroxisome Proliferator- Activator Receptor gamma (PPARγ) is a nuclear 
receptor superfamily of ligand activated transcription factor. In biological system, 
PPARγ plays a crucial role in regulating glucose and lipid metabolism. For that reason, 
PPARγ has drawn enormous attention as a potential target for designing novel drug to 
treat type-2- diabetes.  PPARγ agonist, Rosiglitazone, is the first line drug for improving 
insulin sensitivity of type 2 diabetes.  However, recent studies indicated that 
Rosiglitazone are causing undesired side effects like weight gain, oedema and fluid 
retention. Thus, it is necessary to search for PPARγ agonist for a less complication 
alternative. In this study, virtual screening using molecular docking approach was done 
against 5000 compounds; 3000 compounds were from Nature-Based Drug Discovery 
(NADI®) Database and another 2000 compounds were taken from National Cancer 
Institute (NCI) Diversity Set 1 library. The top 100 hits with lowest free energy of 
binding were further analyzed based on their favorable binding mode. A total of four 
compounds were selected from NCI library and two plants (Temu kunci and Ketumbar) 
were selected from Malaysia natural resources to test against PPARγ in vitro. From the 
assay result, the most active compounds from NCI database were NCI37245, which 
activated PPARγ at EC50 of 43.6nM. While for the selected plants, the methanol crude 
extracts of Temu kunci was more active compared with Ketumbar. The crude extracts of 
Temu kunci activate PPARγ at about 1.5 fold higher compared with Ketumbar (1.6 fold) 
with the EC50 of 50.0ng/mL. Thus, it can be concluded that, docking based virtual 
xx 
 
screening technique has been successfully developed and can be used to select potential 
PPARγ ligand from a pool of small molecules. 
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CHAPTER 1 
INTRODUCTION 
Diabetes mellitus (DM) is a complicated metabolic disorder characterized by 
chronic hyperglycemia or high blood glucose level with fasting blood sugar reading of 
126 mg/dl or higher. Usually diabetes is caused by the defection of insulin secretion, 
insulin resistance of targeted cells or both (American Diabetes Association, 2012). 
Insulin is a hormone which plays important roles in glucose and lipid metabolism. Poor 
control of excessive glucose in the blood will damage the circulation system and organs. 
This eventually brings to the long term complication of diabetes such as heart disease, 
stroke, high blood pressure, retinophathy, nephropathy, amputation (Fajans and Nutting, 
1993), Neuropathy (Maser et al., 2003, Martin et al., 2006) and as well as bond fracture 
(Janghorbani et al., 2006, Lipscombe et al., 2007). 
DM is a well known disease recognized as a health threat worldwide. According 
to WHO, 346 million people in the world have diabetes and in 2011, diabetes was the 
cause of more than 3.5 million deaths in developing country which is almost 80% of 
total diabetes death. Compared with high income countries like United States (US), the 
mortality rate are much lower than the middle income countries. In the same year of 
2011, about 180000 people died in US (Scully, 2012).   
The case of DM is increasing at an alarming rate and has just reached epidemic 
proportion. According to international Diabetes Federation, the prevalence of diabetes 
was estimated to rise from 171 million in 2000 to 366 million in 2030 due to population 
growth, urbanization, increasing prevalence of obesity, physical inactivity and aging of 
the world population (Wild et al., 2004). However, what makes it more alarming is that, 
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most of the people are not aware that they are actually having diabetes. A survey 
conducted by Malaysian Diabetes Association, there were approximately 1.2 million 
people suffer from diabetes in 2007 and it was estimated that more than half are believed 
to have it without realizing they do (Hasan et al., 2011).  
 
1.2 Classification of Diabetes 
There are a few types of DM but the major ones are Type 1 and Type 2 DM. 
Other types of diabetes include gestation diabetes, prediabetes (American Diabetes 
Association, 2012), Latent Autoimmune Diabetes in Adults (LADA) (Pozzilli and Di 
Mario, 2001) and type 3 DM (Monte de la and Wands, 2008).  
 
1.2.1 Prediabetes 
Prediabetes is a new term for impaired fasting glucose  
(IFD) or impaired glucose tolerance (IGT). It is characterized by high glucose levels in 
blood plasma but are yet to be diagnosed as diabetes (American Diabetes Association, 
2012). Recent data show that at least 57 million adults in the U.S. had pre-diabetes in 
2007. Usually there are no symptoms observed on those who have pre-diabetes but, if 
nothing is done to bring down their glucose levels, they are at great risk of developing 
diabetes within about 10 years. Experts are recommending that everyone who has any of 
the risk factors for type 2 diabetes to be tested for prediabetes (Bray, 2008).  
Basically, prediabetes can be diagnosed based on fasting glucose level or glucose 
tolerance level. People with prediabetes usually having impaired fasting glucose (IFG) 
levels of 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l), or impaired glucose 
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tolerance (IGT) of 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l) (American 
Diabetes Association, 2012). The physiological condition of prediabets can be reversed 
in several manners such as physical exercise, weight loss and healthy diet. According 
diabetes prevention program (DPP), reduction of fat and calories intake together with 
physical activites can prevent or delay the development of diabetes from prediabetes 
(Knowler et al., 2002).  
 
1.2.2 Gestational Diabetes Mellitus  
Gestational Diabetes Mellitus (GDM) is a hyperglycemia condition that happens 
in pregnant women, usually in late second trimester of pregnancy. Studies indicated that 
gestational diabetes is due to the hormones from the placenta which affect the function 
of insulin in maintaining euglycaemic control and finally, causing elevated blood 
glucose levels (Bottalico, 2007). According to American Diabetes Association, about 
7% of pregnancies women are complicated with GDM resulting in more than 200000 
cases annually (American Diabetes Association, 2012). Historical studies on type 2 
diabetes women showed that women with gestational diabetes history ussualy have as 
high as 20% risk of developing overt diabetes (Hayes, 2012) and their offsprings are at 
risk of being obese which might later develop type 2 diabetes (Clausen et al., 2008).  
Healthy lifestyle and metformin therapy are recommended by DPP to reduce the 
percentage of developing diabetes of historical GDM women (Ratner et al., 2008). 
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1.1.3 Type 1 Diabetes (T1DM) 
Type 1 DM is also known as insulin dependent diabetes (IDDM) or juvenile 
onset diabetes (American Diabetes Association, 2012). Type 1 DM results from the 
cellular mediated autoimmune destruction of pancreatic β-cells in the islets of 
Langerhans that lead to absolute insulin deficiency (American Diabetes Association, 
2012). According to American Diabetes Association, only 5-10% of all diabetes patients 
in the world encountered as Type 1 DM (American Diabetes Association, 2012). Type 1 
DM is closely related with genetic makeup of pancreatic beta cells and usually occuring 
in genetically susceptible individuals. Genetical profile shown that, 90% of Type 1 DM 
patients are reported to have mutation in genes that encode for Human Leukocyte 
Antigen, HLA (Koshland, 1958). HLA is a protein that plays an important role in human 
body defense system. It presents molecules to the body T-cells to differentiate self cells 
and non-cells. Mutation of HLA genes in T1DM patient had let to autoimmune 
inflammatory attack that destroys the pancreatic beta cells. Thus, insulin injection will 
be the mainstay treatment for Type 1 DM patients (Casey, 2012). 
 
1.1.4 Type 2 Diabetes 
Type 2 DM, previously called as non-insulin dependent DM (NIDDM), is the 
most common diabetes and is characterized by insulin resistance and defection in insulin 
secretion (Butler et al., 2003, American Diabetes Association, 2012). According to 
World Health Organization (WHO), approximately 90% of all diabetic patients in the 
world is Type 2 DM. This phenomenon is usually due to the changes of lifestyle in the 
developing country, where urbanization and economic development have brought to 
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negative impact of lifestyle such as diet changes, less physical activity, and so on. This 
incidence, have also caused to the rise of upper body obesity in the developing country 
(Yoon et al., 2006). Obesity is well known as a main factor that contribute to insulin 
insensitivity of targeted cells (Fradkin, 2012). Obesity was defined as an excess of body 
adiposity (Caballero, 2007). Body mass index (BMI) was used as a standard tools to 
measure body fat based on height and weight, for obese people the BMI is more than 30 
(BMI, 2012). Despite lifestyle and diet changes, psychological conditions (stressed and 
insomnia) (James et al., 2005) and genetic makeup of human (O'Rahilly and Farooqi, 
2006) are also associated with obesity as shown in Figure 1.1. 
Statistical studies on obesity and diabetes prevalence in Asia showed that the 
proportions of people with type 2 diabetes and obesity have increased throughout Asia. 
Asia alone accounts for 60% of world’s diabetes population (Chan et al., 2009) and the 
prevalence of overweight and obesity is increasing parallel with economic development 
and rapid urbanization (Hu, 2011).  
In general, once the cells become resistance to insulin, the function of insulin in 
controlling glucose and lipid metabolism has been cut off and the sugar will remain in 
the blood stream. In order to overcome this problem, pancreatic β-cells will tend to 
produce more insulin to take down the blood sugar level. Prolonging this situation will 
cause hyperinsulinemia where excess level of insulin is found in the circulation system. 
Ultimately, it will affect the β-cell mass to become lesser and lesser and eventually lead 
to insulin dependency and type 2 DM (Butler et al., 2003, Holness and Sugden, 2012). 
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Figure 1.1 Factors contribute to obesity and Type 2 Diabetes Mellitus. All pictures were 
downloaded from Google image (www.google.com). 
 
 
 
 
 
 
 
 
- 7 - 
 
1.2 The Mechanism of Insulin and Glucagon Action in Glucose Homeostasis 
Insulin is an antagonist hormone that helps to maintain glucose homeostasis 
together with glucagon. Inside the cell, glucose was utilized as an energy source and 
stored in the form of glycogen in the muscle and liver cells or as triglyceride in the 
adipose tissues (Albright and Stern, 1998). Glucose is required for cellular respiration 
and also as a building block of organic compounds such as lipid and glycogen as for the 
energy source. Therefore maintaining glucose level at a normal rank of 90mg/mL in the 
body is a crucial step for cell metabolism process.  
In a normal condition, when glucose level is high, β-cells of pancreas will be 
detected and insulin will be released into the blood. Insulin then acts like a key to unlock 
the door on the membrane cell to allow glucose to go inside the cell to bring down blood 
sugar level (Aronoff et al., 2004); on the other hand, if the blood glucose is lower than 
the normal rank, pancreatic α-cells are stimulated to release glucagon into the 
bloodstream and these glucagon will regulate gluconeogenesis where the stored 
glycogen will be converted into glucose inside the liver and released into bloodstream to 
bring back glucose level in the body (Orci et al., 1975, Gerich et al., 1979). 
Insulin and glucagon are working in the opposition role but they are 
interconnected to each other to regulate glucose homeostasis. In other words, if one of 
them fails or unable to perform their role in glucose homeostasis then the body will 
become unbalance. In the case of T2DM, excessive glucose is found in the bloodstream 
and the body cells are unable to take up the glucose due to insulin resistance of the cells. 
Therefore is it worth for us to look inside the molecular mechanism of insulin action on 
glucose homeostasis to understand the main reason for the cells to become insulin 
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resistance. This will hopefully allow us to search for the possible solution to overcome 
the problem. 
 
1.2.1 Insulin mediate Glucose Transporter 4 translocation 
Insulin mediate cellular glucose uptake through the translocation of Glucose 
Transporter 4 (GLUT 4) from intracellular to plasma membrane. GLUT 4 is a protein, 
primarily found in adipose tissue and muscle, which facilitated glucose uptake through 
passive transport by forming an aqueous pore across the plasma membrane (Bell et al., 
1993, Bryant et al., 2002a). Translocation of GLUT4 involves two important pathway 
stimulated by insulin which is PI3 kinase /Akt pathway and CAP/Cbl pathway as shown 
in Figure 1.2 (Bryant et al., 2002b, Jun et al., 2008). 
Insulin will first bind to the Insulin Receptor (IR) on the membrane surface and 
then activates the tyrosine domain (Yu and Czech, 1984). The activated insulin receptor 
then trans-phosphorylates and subsequently recruits insulin receptor substrate 1-4 
protein, Shc and Cbl (Holland et al., 2008). These events led to the activation of 
downstream signaling pathway which involves glucose transport, glycogen and protein 
synthesis as well as mitogenesis (Kohn et al., 1996, White, 1998, Alessi and Cohen, 
1998). One of the important pathways involves in glucose uptake and glycogen synthesis 
is PI3 kinase/Akt pathway (Bryant et al., 2002b). 
 
1.2.1.1 PI3 kinase/Akt pathway 
PI3 kinase /Akt pathway plays a pivotal role in GLUT4 translocation. Validation 
of the important function of PI3K is derived from the pharmacological inhibition of 
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PI3K which blocked the GLUT 4 translocation to the membrane cell and glucose uptake 
(Shang et al., 2008). Phosphorylation of IRS stimulated the activation of 
Phosphatidylinositol-3 kinase (PI3K) by binding to the regulator p85 subunit and 
activates its catalytic p110 subunit. Activation of PI3K lead to the formation of 
Phosphatidylinositol 3,4,5 triphosphate (PIP3) and subsequently recruit the PI3K-
dependent serine/threonine kinases (PDK1) and activate the Akt. There are evidence 
supports that activated Akt is requiring for insulin-dependent translocation GLUT4 (Hill 
et al., 1999, Wang et al., 1999, Kohn et al., 1996) 
The activated Akt will to lead phosphorylation of 160kDa Akt substrate (AS160). 
AS160 contains a GTPase-activation protein (GAP) domain for Rabs protein which 
plays critical roles in vesicle formation, movement, and fusion. Phosphorylation of 
AS160 causes the dissociation of AS160 from the GLUT4 storage vesicle, preventing 
AS160 from converting the Rab protein to its inactive GDP form. The activated Rab–
GTP complex then promotes docking and/or fusion of the GLUT4 storage vesicle with 
the plasma membrane and facilitated glucose transportation (Hardie, 2007, Sano et al., 
2003). 
 
1.2.1.2 Cbl/CAP pathway 
Cbl/CAP pathway is another important pathway which works in parallel with 
PI3k/Akt pathway in GLUT4 translocation (Saltiel and Pessin, 2003). Insulin stimulates 
tyrosine phosphorylation of c-Cbl leading to the translocation of Cbl-CAP complex from 
intracellular site to lipid rafts plasma membrane. In the lipid rafts, CAP binds with 
flotillin, a protein within lipid rafts, while Cbl recruits Crkll (adaptor protein) along with 
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C3G, which lead to activation of TC10. Finally, the activated TC10 with it effectors 
(CIP4) will then mediate GLUT4 translocation (Chiang et al., 2001, Symons and Rusk, 
2003). The pivotal role of CAP-Cbl in GLUT4 translocation has been studied by 
expression of CAP mutant, which showed it completely inhibit insulin stimulate uptake 
and GLUT4 translocation (Chunqiu Hou and Pessin, 2003). 
Therefore, it can be concluded that PI3K/Akt and Cbl/CAP pathways are 
important pathways in GLUT4 translocation. Selective inhibition of these pathways 
could contribute to the development of insulin resistance (Shang et al., 2008, Chunqiu 
Hou and Pessin, 2003). This also in turn suggests that, PI3K/Akt and Cbl/CAP pathway 
might be an important pathway for pharmacological study in search for a novel anti-
diabetes drug candidate (Zhang and Moller, 2005). In term of safety issue, Cbl/CAP 
pathway will be a better choice for drug target. This is because, constitutively activation 
of PI3K might lead to tumourigenesis as PI3K is also involved in various cellular 
processes such as cell survival and growth factor transduction pathway (Jaiswal et al., 
2009). Apart from that, down regulation of PI3K regulator subunit could bring to 
protein-protein interactions which may interrupt the metabolism process in the body 
(Okkenhaug and Vanhaesebroeck, 2001, Koyasu, 2003, Mellor et al., 2012). Thus, agent 
that can stimulate Cbl/CAP pathway in GLUT4 translocation may represent new 
therapeutic approaches for insulin resistance. 
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Figure 1.2  Model of PI3K/AKT and Cbl/CAP/TC10 pathway in GLUT4 translocation 
(Jun et al., 2008).  
 
 
 
 
 
 
 
 
 
Flotillin 
- 12 - 
 
1.3 Insulin Resistance 
Looking back, insulin resistance is actually the major cause of T2DM (Kahn et 
al., 2006). Insulin resistance is a metabolic syndrome closely link to various type of 
disease such as T2DM, polycystic ovary syndrome (Dunaif, 1997), obesity and 
hypertension (Bloomgarden, 2002, Saad et al., 2004). However, here focus is set only on 
the relationship between insulin resistance and T2DM and how this relationship can 
bring to discovery of anti-diabetes drug (Kahn et al., 2006). 
 Insulin resistance is a physiological condition where the body cells especially 
muscle and fat cells become resistance to insulin. In other word, the insulin become less 
effective to bring down glucose level in blood stream which eventually will lead to 
hyperglycemia, a major consequence of insulin insensitivity (Lee et al., 2006, Jellinger, 
2009).  
In order to study the mechanism behind the insulin resistance, genetic 
modification of genes that encode protein which directly or indirectly involved in insulin 
signaling pathway will provide crucial information of the genes that related to insulin 
insensitivity (Saad et al., 2004). Table 1.1 showed the phenotypic effect of genetic 
modified mouse towards insulin resistance.  
Genetically inhibited gene expression that encode IR, IRS1 & 2, P85α and β, 
Akt2, Glut4 and PPARγ have shown to cause insulin resistance and diabetes in GM mice, 
while genes that encode protein-tyrosine-phosphate-1B (PTP1B), SH domain containing 
inositol 5-phosphate (SHIP2), TNFα, TNFα receptor and Adiponectin have show to 
improved the insulin sensitivity which mean that agents that stimulated the expression of 
PTP1B, SHIP2, TNFα, TNFα receptor and Adiponectin gene would be 
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Table 1.1 Show the phenotypic effect of genetic modified mouse towards insulin 
resistance. 
Target Gene Genetic 
Modification 
Physiological Respond References 
IR   -/- Severe diabetes (Joshi et al., 1996, Accili et 
al., 1996) 
IRS1 -/- Insulin Resistance (Araki et al., 1994, 
Tamemoto et al., 1994)  
IRS2 -/- Insulin Resistance 
with diabetes 
(Kubota et al., 2000) 
IRS3 -/- No effect on glucose 
homeostasis 
(Liu et al., 1999) 
IRS4 -/- Mild effect on 
glucose homeostasis 
(Fantin et al., 2000) 
P85α and β -/- Lethal (Fruman et al., 2000, Ueki et 
al., 2002) 
P85α and β   +/- hypoglycemia (Fruman et al., 2000, 
Mauvais-Jarvis et al., 2002)  
Akt1 -/- No diabetes (Lawlor et al., 2002) 
Akt2 -/- Insulin resistance 
with diabetes 
(Cho et al., 2001, Garofalo 
et al., 2003, Peng et al., 
2003) 
Glut4 -/- Diabetes (Rossetti et al., 1997) 
Glut4   +/- Diabetes (Stenbit et al., 1997) 
PTP1B -/- enhance insulin 
sensitivity 
(Klaman et al., 2000) 
SHIP2 -/- Improve insulin 
sensitivity 
(Clement et al., 2001) 
TNFα -/- Improve insulin 
sensitivity 
(Uysal et al., 1997) 
TNFα 
receptor 
-/- Improve insulin 
sensitivity 
(Uysal et al., 1998) 
Adiponectin -/- Improve insulin 
sensitivity 
(Maeda et al., 2002) 
PPARγ -/- Severe diabetes (Kubota et al., 1999) 
PPARγ    +/- Improve insulin 
sensitivity 
(Kubota et al., 1999) 
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the main factor to contribute to insulin resistance. All in all, genetically modified on 
selected genes of mice have provided a very clear picture on the genes which are 
involved in the molecular mechanism leading to insulin resistance. 
Apart from that, there are lots of scientific proves that insulin resistance is 
closely related with obesity especially in upper body obesity. Obesity is a medical 
condition in which excess fat accumulated in the body and these fat will store inside a 
specify tissues known as adipose tissue (Kopelman, 2000).    
Adipose tissues are making up of adipocytes or fat cells, it is mainly distribute in 
the hips and thighs for women and upper body for males (Arner, 1997). Previously, 
adipocyte is merely known as an energy or fat storage and has been ignored by most 
scientists for centuries. But after a few decade of intense investigation, it was found out 
that adipocyte is not merely fat storage but served as an endocrine organ, a major factory 
to secrete variety factors that potentially mediate insulin resistance (Mohamed-Ali et al., 
1998).   
As shown in Figure 1.3, In lean state, small adipocytes store incoming fatty acids 
as triglyceride, which can be used to generate energy when caloric need. However 
excessive intake of caloric increases triglyceride input and leads to inflammation of 
adipocyte. This eventually affects the physiological activities of adipocyte by over 
secreting monocyte chemoattractant protein-1 (MCP-1) which takes on more 
macrophage within adipose tissue. Activation of macrophage by cytokine secrete large 
amount of tumour necrosis factor-α (TNFα) (Xu et al., 2003, Sartipy and Loskutoff, 
2003, Weisberg et al., 2003).   
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Figure 1.3 Physiological condition of adipocyte in lean state, pro-inflammatory state 
and inflammatory state (Guilherme et al., 2008). 
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Tumor Necrosis Factor α , TNFα is one of the important factors that contribute to 
insulin resistance that inactivates several molecules which take part in insulin signaling 
pathway such as down regulation of IR, defect of the IR tyrosine kinase activity and 
decreased activity of IRS-1 and PI3 kinase. (Hotamisligil and Spiegelman, 1994, 
Hotamisligil et al., 1995). Study also showed that TNFα secretion led to increased in 
lipolysis and decreased in triglyceride synthesis (Guilherme et al., 2008, Ruan and 
Lodish, 2003). At the same time, it also increased level of circulating FFA and 
accumulation of activated lipids in skeletal muscle, and liver (Lagathu et al., 2006). The 
activated lipid and fatty acid derivatives are known to affect normal metabolic process or 
causing lipotoxicity in the body (Unger, 1995, Unger, 2002). Lastly, prolonged caloric 
overload will also cause adipocyte dysfunction and disrupting functions such as insulin-
stimulated glucose transport, thus triggering insulin resistance (Guilherme et al., 2008) 
But the question is what will be the right target on controlling the inflammatory 
process in adipose tissue that brings to adipocyte dysfunction? Many studies have 
emphasized on the effect of TNFα on insulin resistance, adipogenesis and triglyceride 
storage. However, highlighted here showed that down regulation of peroxisome 
proliferator activated-receptor gamma (PPARγ) is a key element in controlling adipocyte 
inflammation. This has been proven by adding extra TNFα into adipocytes that result in 
rapid decrease of PPARγ mRNA level, inhibit post-transcription process of PPARγ 
protein by up-regulating mitogen-activated protein kinase 4 (MAP4K4) and degrading 
PPARγ protein.  It is clear that, down regulation of PPARγ by TNFα have decreased 
triglyceride storage and increase FFA circulation which in turn lead to insulin 
insensitivity and T2D (Guilherme et al., 2008).  
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It is interesting to note that by activating PPARγ by its agonist, such as 
thiazolidinediones, have shown a very clear effect on decreasing TNFα and antagonize 
the inhibition of insulin signaling by TNFα as well as reversing the overall physiological 
condition of adipocyte that due to TNFα (Sandra C. Souza et al., 1998, Dıaz-Delfın et al., 
2007). Besides that, the activated PPARγ also stimulates c-Cbl-associated protein 
(Lagathu et al.) expression in adipose tissue and increased insulin-stimulated c-Cbl 
phosphorylation pathway in GLUT4 translocation which facilitate glucose uptake as 
discussed previously (Section 1.2.1.2) and at the same time increase insulin sensitivity 
(Ribon et al., 1998, Balasubramanyam and Mohan, 2000). Therefore, it will be valuable 
to study on PPARγ as a potential target on designing drug for T2D as it appears to be the 
principle target in the pathogenesis of T2D.                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
1.4  Peroxisome Proliferator Activated Receptor Gamma 
Peroxisomal Proliferator Activated Receptor gamma (PPARγ) is one of the three 
types of PPAR isoforms, PPAR alpha, PPAR delta and PPAR gamma, and it belongs to 
nuclear receptor superfamily of ligand activated transcription factor. PPARγ plays an 
important role in regulation of adipocyte gene expression and differentiation, insulin 
sensitivity, glucose homeostasis and lipid metabolism. (Berger and Moller, 2002).  
 There are two isoforms of PPARγ that have been found in mice (Tontonoz et al., 
1994a), γ1 and γ2. Both γ1 and γ2 are expressed from the same gene but the levels of 
expression are varying among the tissues. PPARγ1 is expressed in adipose, liver, 
skeletal and cardiac muscle, and macrophages, while PPARγ2 is expressed 
predominantly in adipose tissue (Tontonoz et al., 1994b, Brun et al., 1996). The two 
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isotypes of PPARγ are form due to the post-translational modification process which 
involved different RNA splicing of the same gene and used of different promoter (Zhu et 
al., 1995). The PPARγ2 has an additional 28 amino acids in N-terminal compared to 
PPARγ1. 
Structurally, PPARγ is made up of four domain structures. That are the ligand-
binding domain (LBD) at the COOH- terminal region, which is made up of around 250 
amino acids, a conserved DNA-binding domain encoding,  two zinc fingers and the 
NH2-terminal ligand independent transcriptional activation function (AF-1) domain, 
which regulates PPAR activity and a docking domain for cofactor (Weatherman et al., 
1999, Wilson et al., 2001, Nettles, 2008, Farce et al., 2009).  
Ligand binding domain acts as a hormone binding and also contains dimerization 
motif and transcriptional activation function (AF2) domain associated with helix 12 
(H12) (Sheu et al., 2005, Freedman, 1999). Structural studies indicated that precise 
position of AF2 helix is important for co-activator recruitment and selective genes 
regulation (Gampe et al., 2000, Motani et al., 2009b).   
There are 12 α-helices and 4 short β-sheet folded into sandwich like hydrophobic 
cavity of LBD (Uppenberg et al., 1998).  A special feature of LBD of PPARγ is that, it 
has a big Y- shape cavity within the protein with a total volume of 1300 to 1400 Å 
(Zoete et al., 2007). The cavity is made up of flexible entrance between H3 and β-
strands, which extend from the surface of the protein to create solvent-accessible 
channel and two branching arms with approximately 12.0 Å in length. Flexibility of the 
entrance allows the ligand to enter the binding site of the protein without significantly 
changing the conformation of the LBD (Xu et al., 1999, Lu et al., 2006). While the two 
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arms act as a binding site for the ligand. Arm I is made up of polar residues like His323, 
Tyr327, Lys367, His449 and Tyr473 to create a polar surface while the second arm is 
delimited by Phe226, Pro227, Ile296 and Met329. Both entrance and Arm II are more 
hydrophobic, thus usually occupied by hydrophobic tail of the ligand (Uppenberg et al., 
1998).  
Typically, the binding pockets of PPARγ are more hydrophobic in nature 
compared to the surface and this phenomenon enhances the effect of ionic interaction. 
Ionic interaction is usually important for initial interaction as the drug enters the binding 
site and it is the strongest intermolecular bonds which takes place between two 
functional groups having opposite charge.  
PPARγ can be activated by specific nutrients, non-nutrient endogenous ligands, 
and drug such as thiazolidinediones and glitazone. In the inactivated state, PPARγ forms 
heterodimer with RXR. The PPARγ-RXR complex associated with a group of co-
repressor to prevent deacetylation of Histone to inhibit the gene transcription process. 
Once the ligand bound with PPARγ, the LBD undergoes a conformational change in 
such a way that the AF-2 helix, together with H3 and H4 form a hydrophobic groove 
(Gampe et al., 2000). This results in the dissociation of co-repressor such as SMRT 
(silencing mediator for retinoid and thyroid hormone receptor) from the PPARγ-RXR 
heterodimer and the co-activator molecule is associated to fully activate the PPARγ 
(Lavinsky et al., 1998, Zhu et al., 2000, Glass and Rosenfeld, 2000). The activated 
PPARγ-RXRα complex binds to DNA motif element, PPAR respond elements (PPRE), 
in promoter region of the targeted gene for acyl-CoA oxidase to modulate the gene 
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transcription process as showed in Figure 1.4 (Glass and Rosenfeld, 2000, 
Balasubramanyam and Madras, 2000).  
Currently there are number of co-activators identified and characterized such as 
CREB binding protein (CBP), P300, steroid receptor co-activator  (SRC-1), PPAR 
binding protein (PBP), PPARγ co-activator-1 (PGC-1) and PPAR interacting protein 
(PRIP). The recruitment of co-activator is totally depending on the structure of PPARγ 
which in turn is determined by the ligand type (Balasubramanyam and Madras, 2000, 
Gelman et al., 2007).  
As discuss previously, the unique characteristic of PPARγ LBD with big 
hydrophobic cavity and hydrophilic Arm II has created an environment which can 
recruit a wide variety of natural and synthetic ligand to give different respond. Ligand 
for PPARγ can be classified into three major classes: PPARγ against, PPARγ antagonist, 
and selective PPARγ modulator. But the most famous studied were PPARγ agonists and 
selective PPARγ modulators. 
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Figure 1.4 Mechanism of PPARγ activation and transcriptional regulation of target 
genes (Yki-Jarvinen, 2004). 
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1.4.1 PPARγ Agonists 
PPARγ agonist is a receptor ligand which fully activates PPARγ receptor to 
induce full response of its activity. PPARγ has been shown to be the molecular target for 
thaizolidinediones (TZD), a new class of antidiabetic drug that includes troglitazone 
(Rezulin), rosiglitazon (Avandia), and pioglitazone (Actos) (Shearer and Billin, 2007).  
Pharmaceutically, TZD was used as insulin sensitizer in T2D patients. Administration of 
TZD class drugs such as Rosiglitazon has showed in consistently lower fasting and 
postprandial glucose concentrations as well as free fatty acids and insulin concentration 
in several manners (Nolan et al., 1994, Miyazaki et al., 2001, Bajaj et al., 2004).    
The activated PPARγ stimulates the expression of different set of genes 
particularly involved in lipid and glucose metabolism. According to the “fatty acid steal” 
hypothesis, PPARγ agonists promote fatty acid uptake and storage in adipose tissues by 
enhancing adiponectin secretion. This however increases the adipose tissues mass and 
protects muscle, liver and possibly pancreatic beta cells from exposing to harmful 
metabolic effect of high fatty acid concentration (Martin et al., 1998, Yki-Jarvinen, 
2004).  Apart from that, activation of PPARγ by its agonist also stimulates adipogenesis 
and block the action of TNFα (Peraldi et al., 1997), which inhibits insulin signaling 
pathway as well as TNFα induced glycerol and non-esterified fatty acid release (Souza 
et al., 1998). Hence, activation of PPARγ decreases various signaling molecules such as 
free fatty acids, leptin, and TNFα, which are able to counteract the hypoglycemic action 
of insulin.  
PPARγ agonist molecule usually possesses an acidic head involved in the 
hydrogen bond network, a central aromatic moiety and a hetero-aromatic hydrophobic 
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tail. This topology is preserved in a large number of synthetic PPARγ ligands, which 
belong mainly to five chemical classes: thiazolindinediones, tyrosined-based, indole-
based, propionic-acid and phenylacetic acid derivatives (Giaginis et al., 2009). 
Troglitazone is the first approved TZD drug on the market but was withdraw 
from the marketplace because of the idiosyncratic liver toxicity (Shearer and Billin, 
2007). There are some other PPARγ agonist’s marketed drugs such as rosiglitazon and 
pioglitazon. Both rosiglitazon and pioglitazon have been published by the DrugBank 
with the accession number DB00412 and DB01132 respectively.  
Nevertheless, the marketed TZD classes of PPARγ agonist have been proven to 
have some side effect such as weigth gain, mascular and pulmonary oedema and fluid 
accumulation (Nesto et al., 2003). Oedema is the most undesired side effect for PPARγ 
agonist and is shown in 10-15% of patients treated with TZD. The accumulation of fluid 
and oedema will increase the incident of heart failure (Scheen, 2004). Is it believed that, 
PPAPγ is selectively expressed in the medullar collecting duct and induces the 
expression of the epithelial Na+ channel of γ subunit, which may play an important role 
in PPARγ mediated sodium reabsorption and increase fluid retention (Guan et al., 2005, 
Zhang et al., 2005, Nicholas et al., 2001). Thus, identification of PPARγ-specific target 
gene is necessary for designing a new TZD class PPARγ agonist, which is free from 
fluid retention and oedema. 
The second major problem of TZD treatment is the increased the body weight of 
treated patients. PPARγ is known to be involved in adipogenesis; stimulation of PPARγ 
by TZD will lead to the formation of new adipose tissue that promotes the adipocyte 
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differentiation and lipid accumulation and lastly contributes to increase body weight 
(Shearer and Billin, 2007). 
 
1.4.2 Selective PPARγ Modulator 
Selective PPAR modulator (SPPARM) is selective combinations of agonist and 
antagonist compound, which induced spesific changes of receptor conformation and 
regulate a specific subset of target genes by recruiting particular coregulator. The 
concept of SPPARM was based on the discovery of selective estrogen receptor 
modulator (SERM) drug. Compared with estradiol, a natural ligand for estrogen receptor, 
SERM (tamoxifen) antagonist the activity in endometrium which can lead to 
endometrial hyperplasia and increase the susceptibility to cancer (Shang et al., 2000).  
The functional profile of SERM had brought to the new stage of drug discovery 
involving nuclear receptor by providing a better understanding on the importance of 
selective recruitment of coregulator by nuclear receptor in genes regulation as well as 
emerging the idea of designing selective PPARγ modulaotr. The objective for designing 
the SPPARM is to improve the therapeutic index by modulating the desired biological 
activity while reducing the undesired side effect (Gelman et al., 2007, Shearer and Billin, 
2007). 
 SPPARM can be characterized by its function as full agonist in particular tissue 
with sufficient expression of coactivator and partial agonist or antagonist in the selective 
tissues with adequate concentration of coactivator. Therefore the activities of SPPARM 
are varied according to the cell type and its context (Olefsky and Saltiel, 2000, Miles et 
al., 2000).  
